12/02/07

US$1.5 billion scheme creates market for vaccines

Pneumoccoccal disease is a major public health problem all over the world Copyright: CDC / Mike Miller

By: Talent Ng’andwe

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>US$1.5 billion scheme creates market for vaccines</h1>
<h4>By: Talent Ng’andwe</h4>
</div>
<br />
<br />

<div id="article-body">
<p><P>A US$1.5 billion scheme is set to accelerate the development and availability of new vaccines for neglected diseases.</P><br />
<P>The Advance Market Commitments for Vaccines (AMC) scheme launched last week (9 February) with a pilot project targeting vaccines against pneumoccoccal disease.</P><br />
<P>The project will subsidise poor countries’ vaccine purchases, guaranteeing the purchase and giving vaccine makers the confidence to develop new treatments and build enough production capacity to satisfy global demand. </P><br />
<P>It will run for 7–10 years and include provisions to ensure a long-term sustainable supply and price for the poorest countries. </P><br />
<P>Pneumoccoccal disease kills about 1.6 million people every year. By speeding the research and development process for vaccines, the project could save the lives of 5.4 million children in the developing world by 2030.</P><br />
<P>Executive secretary of the GAVI Alliance, Julian Lob-Levyt, said an early version of a pneumoccoccal vaccine is showing widespread success in developed countries. </P><br />
<P>But he said manufacturers lack the capacity to provide a vaccine well suited to developing countries on a large scale. </P><br />
<P>“We expect that new pneumoccoccal vaccines will reach developing countries by 2010, at least 10 years earlier than if the AMC were not available,” said Lob-Levyt.</P><br />
<P>Vernon Mwaanga, Zambia’s chief government spokesperson welcomed the scheme, which would bring relief to developing countries that cannot afford to buy expensive vaccines. </P><br />
<P>He urged the AMC to extend the programme to other diseases if this pilot proves successful.</P><br />
<P>AMC is a partnership between the Bill and Melinda Gates Foundation and five developed countries — Canada, Italy, Norway, Russia and the United Kingdom. </P><br />
<P>It will be overseen by an independent assessment committee, which will set up and monitor standards for the vaccines. </P><br />
<P>The World Health Organization will help identify promising vaccines to target, and assess their quality, safety and effectiveness. The GAVI Alliance and the World Bank will also help with the initiative’s planning and financial administration.</P>A total of US$1.5 billion has been committed to the project so far.<BR><BR></p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/sub-saharan-africa/news/us15-billion-scheme-creates-market-for-vaccines-ssa/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/sub-saharan-africa/news/us15-billion-scheme-creates-market-for-vaccines-ssa/",null,true])
</script>
</div>

A US$1.5 billion scheme is set to accelerate the development and availability of new vaccines for neglected diseases.

The Advance Market Commitments for Vaccines (AMC) scheme launched last week (9 February) with a pilot project targeting vaccines against pneumoccoccal disease.

The project will subsidise poor countries’ vaccine purchases, guaranteeing the purchase and giving vaccine makers the confidence to develop new treatments and build enough production capacity to satisfy global demand.

It will run for 7–10 years and include provisions to ensure a long-term sustainable supply and price for the poorest countries.

Pneumoccoccal disease kills about 1.6 million people every year. By speeding the research and development process for vaccines, the project could save the lives of 5.4 million children in the developing world by 2030.

Executive secretary of the GAVI Alliance, Julian Lob-Levyt, said an early version of a pneumoccoccal vaccine is showing widespread success in developed countries.

But he said manufacturers lack the capacity to provide a vaccine well suited to developing countries on a large scale.

“We expect that new pneumoccoccal vaccines will reach developing countries by 2010, at least 10 years earlier than if the AMC were not available,” said Lob-Levyt.

Vernon Mwaanga, Zambia’s chief government spokesperson welcomed the scheme, which would bring relief to developing countries that cannot afford to buy expensive vaccines.

He urged the AMC to extend the programme to other diseases if this pilot proves successful.

AMC is a partnership between the Bill and Melinda Gates Foundation and five developed countries — Canada, Italy, Norway, Russia and the United Kingdom.

It will be overseen by an independent assessment committee, which will set up and monitor standards for the vaccines.

The World Health Organization will help identify promising vaccines to target, and assess their quality, safety and effectiveness. The GAVI Alliance and the World Bank will also help with the initiative’s planning and financial administration.

A total of US$1.5 billion has been committed to the project so far.